Preserved left ventricular structure and function in mice with cardiac sympathetic hyperinnervation

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 289, Issue 4 58-4, 2005, Pages

  Kiriazis, Helen ^a   Du, Xiao Jun ^a   Feng, Xinheng ^a   Hotchkin, Elodie ^a   Marshall, Tanneale ^a   Finch, Samara ^a   Gao, Xiao Ming ^a   Lambert, Gavin ^a   Choate, Julia K ^b   Kaye, David M ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Catecholamine; Echocardiography; Myocardial contraction; Nerve growth factor; Transgenic

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CATECHOLAMINE; ISOPRENALINE; NERVE GROWTH FACTOR; NEUROTROPHIN; NORADRENALIN;

ADRENERGIC STIMULATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA PRESSURE; ARTICLE; AUTOPSY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GENE OVEREXPRESSION; HEART ATRIUM ENLARGEMENT; HEART CATHETERIZATION; HEART CONTRACTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; HEART RIGHT VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; M MODE ECHOCARDIOGRAPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYMPATHETIC INNERVATION; SYMPATHETIC TONE; SYNAPTIC TRANSMISSION; SYSTOLIC BLOOD PRESSURE; TRANSGENIC MOUSE;

ADRENERGIC BETA-AGONISTS; ANIMALS; ECHOCARDIOGRAPHY; FEMALE; GENE EXPRESSION; HEART; HYPERTROPHY, RIGHT VENTRICULAR; ISOPROTERENOL; MALE; MICE; MICE, TRANSGENIC; MYOCARDIUM; NERVE GROWTH FACTOR; NOREPINEPHRINE; SYMPATHETIC NERVOUS SYSTEM; TRITIUM; VENTRICULAR FUNCTION, LEFT;

EID: 25444450269     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.01010.2004     Document Type: Article

References (40)

1. Andrade-Rozental AF, Rozental R, Hassankhani A, Spray DC, and Federoff HJ. Characterization of two populations of ectopic cells isolated from the hearts of NGF transgenic mice. Dev Biol 169: 533-546, 1995.
2. 2-adrenergic receptors. Trends Cardiovasc Med 12: 287-294, 2002.
3. Briest W, Holzl A, Rassler B, Deten A, Leicht M, Baba HA, and Zimmer HG. Cardiac remodeling after long term norepinephrine treatment in rats. Cardiovasc Res 52: 265-273, 2001.
4. Bristow MR, Hershberger RE, Port JD, Gilbert EM, Sandoval A, Rasmussen R, Cates AE, and Feldman AM. β-Adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 82: 112-125, 1990.
5. Choate JK and Feldman R. Neuronal control of heart rate in isolated mouse atria. Am J Physiol Heart Circ Physiol 285: H1340-H1346, 2003.
6. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, and Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311: 819-823, 1984.
7. 2-Adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. Circulation 101: 71-77, 2000.
8. Du XJ, Fang L, Gao XM, Kiriazis H, Feng X, Hotchkin E, Finch AM, Chaulet H, and Graham RM. Genetic enhancement of ventricular contractility protects against pressure-overload-induced cardiac dysfunction. J Mol Cell Cardiol 37: 979-987, 2004.
9. 2-adrenergic receptors in the heart. Cardiovasc Res 48: 448-454, 2000.
10. Eichhorn EJ and Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation 94: 2285-2296, 1996.
11. Eisenhofer G, Smolich JJ, and Esler MD. Disposition of endogenous adrenaline compared to noradrenaline released by cardiac sympathetic nerves in the anaesthetized dog. Naunyn Schmiedebergs Arch Pharmacol 345: 160-171, 1992.
12. 1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 96: 7059-7064, 1999.
13. Esler M, Jennings G, Lambert G, Meredith I, Horne M, and Eisenhofer G. Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. Physiol Rev 70: 963-985, 1990.
14. Esler M, Kaye D, Lambert G, Esler D, and Jennings G. Adrenergic nervous system in heart failure. Am J Cardiol 80: 7L-14L, 1997.
15. Gilbert EM, Olsen SL, Renlund DG, and Bristow MR. β-Adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am J Cardiol 71: 23C-29C, 1993.
16. Goldstein DS, Eisenhofer G, Stull R, Folio CJ, Reiser HR, and Kopin IJ. Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J Clin Invest 81: 213-220, 1988.
17. Goldstein S. Benefits of β-blocker therapy for heart failure: weighing the evidence. Arch Intern Med 162: 641-648, 2002.
18. Hassankhani A, Steinhelper ME, Soonpaa MH, Katz EB, Taylor DA, Andrade-Rozental A, Factor SM, Steinberg JJ, Field LJ, and Federoff HJ. Overexpression of NGF within the heart of transgenic mice causes hyperinnervation, cardiac enlargement, and hyperplasia of ectopic cells. Dev Biol 169: 309-321, 1995.
19. Heath BM, Xia J, Dong E, An RH, Brooks A, Liang C, Federoff HJ, and Kass RS. Overexpression of nerve growth factor in the heart alters ion channel activity and β-adrenergic signalling in an adult transgenic mouse. J Physiol 512: 779-791, 1998.
20. Ip NY and Yancopoulos GD. The neurotrophins and CNTF: two families of collaborative neurotrophic factors. Annu Rev Neurosci 19: 491-515, 1996.
21. sα overexpression. Circ Res 78: 517-524, 1996.
22. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, and Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 26: 1257-1263, 1995.
23. Kaye DM, Vaddadi G, Gruskin SL, Du XJ, and Esler MD. Reduced myocardial nerve growth factor expression in human and experimental heart failure. Circ Res 86: E80-E84, 2000.
24. Lambert GW and Jonsdottir IH. Influence of voluntary exercise on hypothalamic norepinephrine. J Appl Physiol 85: 962-966, 1998.
25. 1B- adrenergic receptor induces dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 281: H931-H938, 2001.
26. Levine TB, Francis GS, Goldsmith SR, Simon AB, and Cohn JN. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 49: 1659-1666, 1982.
27. Lewin GR and Barde YA. Physiology of the neurotrophins. Annu Rev Neurosci 19: 289-317, 1996.
28. 2- adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 101: 1707-1714, 2000.
29. Lockhart ST, Turrigiano GG, and Birren SJ. Nerve growth factor modulates synaptic transmission between sympathetic neurons and cardiac myocytes. J Neurosci 17: 9573-9582, 1997.
30. Mann DL. Basic mechanisms of disease progression in the failing heart: the role of excessive adrenergic drive. Prog Cardiovasc Dis 41: 1-8, 1998.
31. Matsubara H, Takaki M, Yasuhara S, Araki J, and Suga H. Logistic time constant of isovolumic relaxation pressure-time curve in the canine left ventricle. Better alternative to exponential time constant. Circulation 92: 2318-2326, 1995.
32. Medvedev OS, Esler MD, Angus JA, Cox HS, and Eisenhofer G. Simultaneous determination of plasma noradrenaline and adrenaline kinetics. Responses to nitroprusside-induced hypotension and 2-deoxyglucose-induced glucopenia in the rabbit. Naunyn Schmiedebergs Arch Pharmacol 341: 192-199, 1990.
33. Micera A, Vigneti E, Pickholtz D, Reich R, Pappo O, Bonini S, Maquart FX, Aloe L, and Levi-Schaffer F. Nerve growth factor displays stimulatory effects on human skin and lung fibroblasts, demonstrating a direct role for this factor in tissue repair. Proc Natl Acad Sci USA 98: 6162-6167, 2001.
34. Palermo J, Gulick J, Colbert M, Fewell J, and Robbins J. Transgenic remodeling of the contractile apparatus in the mammalian heart. Circ Res 78: 504-509, 1996.
35. Percy E, Kaye DM, Lambert GW, Gruskin S, Esler MD, and Du XJ. Catechol-O-methyltransferase activity in CHO cells expressing norepinephrine transporter. Br J Pharmacol 128: 774-780, 1999.
36. Qin F, Vulapalli RS, Stevens SY, and Liang CS. Loss of cardiac sympathetic neurotransmitters in heart failure and NE infusion is associated with reduced NGF. Am J Physiol Heart Circ Physiol 282: H363-H371, 2002.
37. Sofroniew MV, Howe CL, and Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 24: 1217-1281, 2001.
38. Tan TP, Gao XM, Krawczyszyn M, Feng X, Kiriazis H, Dart AM, and Du XJ. Assessment of cardiac function by echocardiography in conscious and anesthetized mice: importance of the autonomic nervous system and disease state. J Cardiovasc Pharmacol 42: 182-190, 2003.
39. Wakade AR and Bhave SV. Facilitation of noradrenergic character of sympathetic neurons by co-culturing with heart cells. Brain Res 458: 115-122, 1988.
40. Wakade AR, Wakade TD, Poosch M, and Bannon MJ. Noradrenaline transport and transporter mRNA of rat chromaffin cells are controlled by dexamethasone and nerve growth factor. J Physiol 494: 67-75, 1996.